FDA inspection
Cosette Pharmaceuticals, Inc.: FDA inspection ending Dec 21, 2006
FDA inspection 455593 · Voluntary Action Indicated (VAI) · South Plainfield, NJ
Key facts
| Inspection ID | 455593 |
|---|---|
| Firm | Cosette Pharmaceuticals, Inc. |
| FEI number | 2210277 |
| Address | 111 Coolidge St |
| City | South Plainfield |
| State | NJ |
| ZIP | 07080-3801 |
| Fiscal year | 2007 |
| Inspection end date | Dec 21, 2006 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data